SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* ROBERTS EIRY (Last) (First) (Middle) 6027 EDGEWOOD BEND CT. (Street) SAN DIEGO CA 92130 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/28/2026	3. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [ NBIX ] Foreign Trading Symbol
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) Chief Medical Officer	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	51,331(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	(2)	02/06/2030	Common Stock	17,147	102.9	D
Non-Qualified Stock Option	(3)	02/08/2031	Common Stock	48,199	117.63	D
Non-Qualified Stock Option	(4)	01/31/2032	Common Stock	60,005	79.02	D
Incentive Stock Option	(5)	02/13/2033	Common Stock	965	103.52	D
Non-Qualified Stock Option	(5)	02/13/2033	Common Stock	51,567	103.52	D
Incentive Stock Option	(6)	02/13/2034	Common Stock	747	133.84	D
Non-Qualified Stock Option	(6)	02/13/2034	Common Stock	21,782	133.84	D
Non-Qualified Stock Option	(7)	12/17/2034	Common Stock	27,770	136.69	D
Incentive Stock Option	(8)	02/12/2035	Common Stock	853	117.18	D
Non-Qualified Stock Option	(8)	02/12/2035	Common Stock	42,408	117.18	D
Non-Qualified Stock Option	(9)	02/13/2036	Common Stock	10,087	124.12	D
Restricted Stock Unit	(10)	(10)	Common Stock	2,114	(11)	D
Restricted Stock Unit	(12)	(12)	Common Stock	2,242	(11)	D
Restricted Stock Unit	(13)	(13)	Common Stock	2,743	(11)	D
Restricted Stock Unit	(14)	(14)	Common Stock	6,081	(11)	D
Restricted Stock Unit	(15)	(15)	Common Stock	2,949	(11)	D

Explanation of Responses:

1. 50,146 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

2. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

3. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

4. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

5. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

6. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

7. Represents an option of which 1/4 of the shares underlying the option became vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028.

8. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

9. Represents option of which 1/12th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.

10. Represents Restricted Stock Units (RSUs) remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, vested as to 2,113 shares on February 13, 2026, and will vest as to 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.

11. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

12. Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, vested as to 1,121 shares on February 13, 2026, and will vest as to 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.

13. Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, vested as to 1,372 shares on February 13, 2026, and will vest as to 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.

14. Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,027 shares on February 12, 2026, and will vest as to 2,027 shares on February 12, 2027, 2,027 shares on February 12, 2028, and 2,027 shares on February 12, 2029, subject to the terms and conditions of the award.

15. Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2026. In accordance with the terms of the RSU, the award will vest in full as to 2,949 shares on February 13, 2027, subject to the terms and conditions of the award.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

(For Executing Forms 3, 4, and 5):

Know all by these presents, that the undersigned hereby constitutes
and appoints each of Kyle W. Gano, Matthew C. Abernethy, and
Darin Lippoldt of Neurocrine Biosciences, Inc. (the "Company"),
signing individually, the undersigned's true and lawful attorneys-in-fact
and agents to:

(1) prepare, execute in the undersigned's name
and on the undersigned's behalf, and submit to the Securities and Exchange
Commission (the "SEC") Forms 3, 4 and 5 (including any amendments thereto)
in accordance with Section 16(a) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), and the rules thereunder in the undersigned's
capacity as an officer, director or beneficial owner of more than 10% of a
registered class of securities of the Company;

(2) do and perform any and all acts for and on behalf of the undersigned
that may be necessary or desirable to execute such Forms 3, 4 or 5
(including amendments thereto) and timely file such forms with the
SEC and any stock exchange or any similar authority; and

(3) take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required of the undersigned,
it being understood that the documents executed by such attorney-in-fact
on behalf of the undersigned pursuant to this Power of Attorney shall be
in such form and shall contain such terms and conditions as such attorney-
in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents
and purposes as the undersigned might or could do if personally present,
with full power of substitution or revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-fact,
and their substitutes, in serving in such capacity at the request of
the undersigned, are not assuming (nor is the Company assuming)
any of the undersigned's responsibilities to comply with Section 16
of the Exchange Act.

This Power of Attorney shall remain in full force and effect until
the earliest to occur of (a) the undersigned is no longer required to
file Forms 3, 4 and 5 with respect to the undersigned's holdings of
and transactions in securities issued by the Company, (b)
revocation by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed
by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of the date written below.

Date:  2-October-2026
/s/ Eiry Roberts, M.D.
Name: Eiry Roberts, M.D.